POTASSIUM CHLORIDE 0.22% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Potassium chloride acts as a source of potassium ions, essential for maintenance of cellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Dextrose provides caloric support and is metabolized to carbon dioxide and water, yielding energy. Sodium chloride maintains osmotic balance and fluid distribution.
| Metabolism | Potassium: primarily excreted unchanged by kidneys. Dextrose: metabolized via glycolysis and Krebs cycle. Sodium chloride: not metabolized; excreted in urine and sweat. |
| Excretion | Potassium: primarily renal (>90%) as K+; chloride: renal, following Na+ and Cl- reabsorption. Dextrose: metabolized. Sodium and chloride: renal handling matches intake. No biliary/fecal elimination for these ions. |
| Half-life | Potassium: Not applicable as the drug contains potassium, which distributes and is regulated; no terminal elimination half-life. Dextrose: variable, but glucose half-life ~2-4 hours depending on insulin. Sodium and chloride: long half-life, regulated by kidneys. Clinical context: drug used for repletion, not a typical pharmacokinetic agent. |
| Protein binding | Potassium: not significantly bound to plasma proteins (<10%). Dextrose: not bound. Sodium and chloride: not bound. |
| Volume of Distribution | Potassium: ~0.5 L/kg (total body water), but distributes mainly in intracellular fluid (98%); clinical meaning: small changes in serum K+ reflect large body stores. Dextrose: ~0.2 L/kg (extracellular water). Sodium: ~0.15 L/kg (extracellular fluid). Chloride: similar to sodium. |
| Bioavailability | IV: 100% for all components. No oral or other routes for this product. |
| Onset of Action | IV infusion: immediate for electrolyte repletion; clinical effect (e.g., correction of hypokalemia) within minutes to hours depending on infusion rate. Not applicable for other routes. |
| Duration of Action | Duration depends on infusion rate and patient's renal function; typically, effects persist while infusion continues and decline post-infusion over hours. For hypokalemia correction, post-infusion redistribution may last 4-6 hours. |
| Molecular Weight | 74.55 |
Intravenous infusion. Dose depends on electrolyte requirements, typically for maintenance or replacement. Potassium: 10-20 mEq/hour, not exceeding 20 mEq/hour or 200 mEq/day. Dextrose 10%: 100-200 mL/hour, not to exceed glucose infusion rate of 5 mg/kg/min. Sodium chloride 0.45%: as needed based on sodium deficit and fluid balance. Administer via central or peripheral line.
| Dosage form | INJECTABLE |
| Renal impairment | CrCl 20-50 mL/min: reduce potassium infusion rate by 25-50%. CrCl <20 mL/min: avoid potassium unless severely deficient and serum K+ monitored closely; use with extreme caution. Dextrose and sodium adjustments not typically required unless specific deficits present. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: reduce potassium infusion rate by 50% and monitor serum K+ frequently. Child-Pugh C: avoid potassium chloride unless absolutely necessary; use with caution due to risk of hyperkalemia. Dextrose may be adjusted if hepatorenal syndrome present. |
| Pediatric use | Weight-based. Potassium: 2-4 mEq/kg/day, infusion rate not exceeding 1 mEq/kg/hour. Dextrose 10%: 5-10 mg/kg/min (as glucose). Sodium chloride 0.45%: 2-6 mEq/kg/day. Monitor serum electrolytes and glucose closely. |
| Geriatric use | Start at lower end of dosing range due to age-related decline in renal function. Potassium infusion rate: initial 5-10 mEq/hour, titrate based on serum K+. Dextrose infusion: limit to 100 mL/hour to avoid hyperglycemia. Sodium: use caution in patients with hypertension or heart failure; monitor volume status. |
| 1st trimester | Potassium chloride, dextrose, and sodium chloride are essential nutrients; use is generally considered safe in pregnancy when clinically indicated. However, avoid excessive administration to prevent electrolyte imbalances. |
| 2nd trimester | Same as T1. Monitor serum electrolytes and fluid balance closely. |
| 3rd trimester | Same as T1. During labor and delivery, caution due to risk of hyperglycemia in the neonate if maternal glucose is elevated. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | All components (potassium, chloride, dextrose, sodium) cross the placenta. Dextrose crosses by facilitated diffusion; electrolytes cross via active transport and diffusion. Fetal levels equilibrate with maternal levels. |
| Breastfeeding | Potassium chloride, dextrose, and sodium chloride are normal components of human milk. Administration of this solution is compatible with breastfeeding. Monitor maternal electrolyte and glucose levels as appropriate. |
| Lactation Rating | L1 - Safe |
| Teratogenic Risk | Potassium administration is generally considered safe during pregnancy when used for appropriate indications. No teratogenic effects have been reported with potassium chloride, dextrose, or sodium chloride at standard infusion rates. However, high potassium levels may cause maternal hyperkalemia, which can lead to fetal arrhythmias or cardiac arrest. Hypotonic or hypertonic dextrose solutions may cause maternal hyperglycemia, which is associated with fetal macrosomia, neonatal hypoglycemia, and increased risk of congenital anomalies if uncontrolled. Sodium chloride overload may worsen maternal edema or hypertension. Across all trimesters, the risk is primarily indirect via maternal electrolyte and glucose disturbances rather than direct teratogenicity. |
| Fetal Monitoring | Monitor serum potassium, glucose, and sodium levels periodically during infusion, especially in patients with renal impairment, diabetes, or preeclampsia. Assess fluid balance and signs of hyperkalemia (ECG changes, muscle weakness), hyperglycemia (blood glucose), or fluid overload (edema, hypertension). Fetal monitoring (non-stress test or biophysical profile) may be warranted in cases of significant maternal electrolyte or glucose disturbances. |
| Fertility Effects | No known adverse effects on fertility. Potassium, dextrose, and sodium chloride are essential nutrients and do not impair reproductive function when used at therapeutic doses. |
■ FDA Black Box Warning
No FDA black box warning specific to this combination product.
| Common Effects | fluid replacement |
| Serious Effects |
HyperkalemiaHyperglycemia with ketoacidosis (unless corrected)HypernatremiaHypersensitivity to any componentPulmonary edema (due to risk of fluid overload)Renal failure with oliguria or anuria (unless on dialysis)
| Precautions | Risk of hyperkalemia, especially in patients with renal impairment or receiving potassium-sparing diuretics, Fluid overload in patients with heart failure, renal impairment, or cirrhosis, Hyperglycemia in patients with diabetes mellitus or impaired glucose tolerance, Monitor serum electrolytes, glucose, and fluid balance during administration |
| Food/Dietary | No direct food interactions. However, dietary potassium intake should be considered when monitoring total potassium load. Patients on potassium-sparing diuretics or ACE inhibitors should be aware of additional potassium sources. |
| Clinical Pearls | This combination solution provides maintenance fluids with potassium supplementation. Monitor serum potassium levels closely, especially in patients with renal impairment. Do not administer unless solution is clear and container intact. Use with caution in patients with heart failure, as the dextrose and sodium load may precipitate fluid overload. Rate of administration should be adjusted based on clinical status and electrolyte monitoring. |
| Patient Advice | Report any signs of fluid overload (shortness of breath, swelling) or electrolyte imbalance (muscle weakness, irregular heartbeat). · This medication is typically given as an infusion; do not adjust the rate yourself. · Inform your healthcare provider if you have kidney problems or heart failure. |
Loading safety data…